ERS Genomics and Lepton Prescribed drugs LTD Enter CRISPR/Cas9 License Settlement

ERS Genomics and Lepton Prescribed drugs LTD Enter CRISPR/Cas9 License Settlement

Lepton Pharmaceutical LTD is a biotechnology firm growing a proprietary, breakthrough know-how (Castling Know-how) to considerably enhance adaptive cell-mediated immune response (T-cells, CAR-T-cells, NK-cells.)

Dr. Daniel Zurr, CEO of Lepton stated: “We’re very happy to determine this relationship and license settlement with ERS Genomics. It’s going to significantly help us to develop our revolutionary Castling know-how to considerably enhance immune cells effectivity and longevity to combat most cancers.”

Eric Rhodes, CEO at ERS Genomics added: “Lepton’s Castling know-how has nice potential to influence the sphere of immunotherapies and we’re happy to assist allow Lepton in pursuing this thrilling strategy.”

The Castling know-how is a proprietary, miRNA-based normal know-how platform, primarily consisting of the manipulation of miRNA expression to attain enhanced efficacy and longevity (diminished exhaustion) of cell-based therapies. miRNAs are noncoding RNAs that every impacts the expression of a whole lot of coding genes. The Castling know-how permits, in a single gene enhancing occasion within the immune cell (both allogeneic or autologous), to influence the expression of a mess of genes within the immune cells, as soon as such miRNAs penetrate the microenvironment of most cancers cells. This know-how goals to revolutionize the immune cell most cancers remedy discipline.

 Monetary particulars of the settlement are usually not disclosed.

About ERS Genomics

ERS Genomics is a biotechnology firm primarily based in Dublin, Eire. The corporate was fashioned to supply broad entry to the foundational CRISPR/Cas9 mental property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses can be found for analysis and sale of services and products throughout a number of fields together with: analysis instruments, kits, reagents; discovery of novel targets for therapeutic intervention; cell strains for discovery and screening of novel drug candidates; GMP manufacturing of healthcare merchandise; companion animal and livestock well being; manufacturing of commercial supplies corresponding to enzymes, biofuels and chemical substances; and artificial biology. For extra data please go to

About Lepton Prescribed drugs

Lepton Prescribed drugs LTD. relies in Israel. Lepton focuses on refined and exact silencing of coding RNA expression by small non-coding RNA molecules, working by way of the DROSHA/DICER/RISC pathways, small interfering RNA (siRNA), and microRNA (miRNA), to develop services and products to, finally, enhance therapies for underserved ailments and enhance and alter sufferers’ lives. For extra data please go to

Media contact: 

Dara O’Donnell
ERS Genomics
Tel: + 353-1-539 0083


ERS Genomics and Lepton Prescribed drugs LTD Enter CRISPR/Cas9 License Settlement